Evommune, Inc. (EVMN)
20.70
+0.21
(+1.02%)
USD |
NYSE |
Jun 11, 16:00
20.70
0.00 (0.00%)
After-Hours: 18:34
Evommune Shareholders Equity (Quarterly) : 304.56M for March 31, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 304.56M |
| December 31, 2025 | 205.57M |
| September 30, 2025 | -183.14M |
| Date | Value |
|---|---|
| June 30, 2025 | -171.23M |
| March 31, 2025 | -158.24M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Apogee Therapeutics, Inc. | 1.256B |
| Kymera Therapeutics, Inc. | 1.540B |
| Mineralys Therapeutics, Inc. | 638.14M |
| GRAIL, Inc. | 2.501B |
| MapLight Therapeutics, Inc. | 399.83M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 322.46M |
| Total Liabilities (Quarterly) | 17.90M |
| Debt to Equity Ratio | 0.0299 |
| Current Ratio | 20.36 |
| Net Debt Paydown Yield | -0.22% |